Ginkgo biloba (EGb 761)
Standardised Ginkgo biloba leaf extract (EGb 761: 24% flavonol glycosides + 6% terpene lactones). Ginkgolide B competitively antagonises the PAF receptor, reducing platelet aggregation and improving peripheral circulation. Flavonoid antioxidants scavenge ROS, protect mitochondria, and boost endothelial NO bioavailability. Evidence is modest and inconsistent across dementia and tinnitus; claudication data are more reproducible. Significant antiplatelet activity creates clinically relevant bleeding risk with warfarin and aspirin.
Overview
Ginkgo biloba is the sole surviving species of the division Ginkgophyta — a “living fossil” with an unbroken fossil record extending 270 million years. The fan-shaped leaves of this deciduous tree are the pharmacological source; cultivated extensively in China, South Korea, France, and the United States. It is one of the highest-selling herbal supplements globally by volume, with annual global market exceeding $1 billion. Traditional use spans over 2,000 years in Chinese medicine, where leaves were used for cardiovascular support and seeds (bai guo) for respiratory and urinary complaints.
A critical safety note: seeds contain ginkgotoxin (4’-methoxypyridoxine), a neurotoxin that antagonises pyridoxine (vitamin B6) and can cause seizures, especially in children. Raw or excessive seed ingestion is dangerous. All medicinal preparations uniformly use leaf extract only. The modern pharmaceutical-grade preparation is EGb 761 (Dr. Willmar Schwabe GmbH), standardised to 24% flavonol glycosides (quercetin, kaempferol, isorhamnetin glycosides — the antioxidant fraction) and 6% terpene lactones (ginkgolides A, B, C, J, and bilobalide — the vasoactive/PAF-antagonist fraction). Raw ginkgolic acids, potent skin sensitisers that may also be mutagenic, are removed to <5 ppm in EGb 761. Non-standardised preparations may lack the terpene lactone fraction entirely and have not been validated in clinical trials.
Ginkgo’s popularity has driven substantial clinical trial investment and multiple systematic reviews, making its evidence profile better characterised than most botanical medicines — though the overall clinical effect remains modest and inconsistently demonstrated. It is licensed as a pharmaceutical drug in Germany and France; in the United States it is regulated as a dietary supplement.
Mechanism of Action
PAF Receptor Antagonism — Ginkgolide B (Primary Vasoactive Mechanism)
PAF (platelet-activating factor)
1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine
│
│ binds PAFR (Gi-coupled GPCR)
▼
Platelet activation: aggregation, degranulation, thromboxane synthesis
Neutrophil activation: oxidative burst
Vasodilation at physiological concentrations
Ginkgolide B ─── competitive antagonist at PAFR lipophilic binding pocket
│ (IC50 ~0.5–2 μM; structural PAF mimic)
│
▼ Effect of ginkgolide B:
↓ PAF-induced platelet aggregation and degranulation
↓ Thromboxane synthesis
Increased bleeding time
Clinically relevant interaction with warfarin / aspirin
- Ginkgolide B (primary): Structurally mimics PAF at the lipophilic binding pocket of PAFR; competitive antagonism at IC50 ~0.5–2 μM. Ginkgolides A, C, J show weaker but additive PAF antagonism.
- NO bioavailability: Flavonoid antioxidants (quercetin, kaempferol) inhibit superoxide-mediated NO quenching, preserving endothelial NO half-life. Flavonoids also upregulate eNOS expression and activity, increasing NO production. Net result: cerebral and peripheral arterial vasodilation.
- Mitochondrial protection: Flavonoids reduce mitochondrial ROS generation (Complex I/III leakage) and prevent cytochrome c release under oxidative stress conditions, protecting neuronal energy metabolism.
- Neuroprotection: Bilobalide inhibits NMDA receptor-mediated excitotoxicity; ginkgolide J inhibits AIF (apoptosis-inducing factor) release from mitochondria; flavonoids inhibit amyloid-β aggregation in vitro and support mitochondrial biogenesis via PGC-1α.
Pleiotropic Effects
Cerebral Blood Flow
PAF antagonism (ginkgolide B) reduces platelet microaggregates and improves microvascular flow. eNOS upregulation and NO preservation via antioxidant flavonoids promote cerebral vasodilation, increasing blood flow to regions at risk of ischaemia in aging and cognitive decline.
Peripheral Circulation
Same NO-mediated vasodilation mechanism improves peripheral arterial flow. EGb 761 at 120–160 mg/day reproducibly increases pain-free walking distance by 30–100 m in claudication patients across multiple RCTs — the most consistent clinical signal in the ginkgo evidence base.
Amyloid & Neurodegeneration
Quercetin, kaempferol, and isorhamnetin glycosides inhibit amyloid-β β-sheet formation in vitro and reduce amyloid-induced mitochondrial dysfunction. Ginkgolide J inhibits AIF-triggered apoptosis; bilobalide blocks NMDA excitotoxicity. Human neuroimaging data confirming these mechanisms are limited.
Monoamine Modulation
Weak inhibition of MAO-A and MAO-B has been reported. This is not considered a primary mechanism and the clinical relevance is uncertain, but it may contribute to the mood and cognitive effects reported in some dementia trials and raises a theoretical concern for interaction with MAOIs and SSRIs.
Clinical Use & Dosing
| Indication | Evidence Level | Standard Dose (EGb 761) | Duration Studied |
|---|---|---|---|
| Dementia (Alzheimer’s / vascular) | Low–Moderate | 120–240 mg/day in 2 divided doses | 12–52 weeks |
| Peripheral arterial disease / claudication | Moderate | 120–160 mg/day in 2 divided doses | 12–24 weeks |
| Tinnitus | Low (inconsistent) | 120–160 mg/day | 12 weeks |
| Altitude sickness (prophylaxis) | Low (contradictory) | 80–120 mg twice daily | Started 2 days before ascent |
| Age-related cognitive decline (normal) | Low (inconsistent) | 120 mg/day | 12–24 weeks |
Important: The only clinically validated standardised extract is EGb 761. Non-standardised ginkgo supplements cannot be assumed equivalent and have not been validated in trials. Ginkgolic acid content must be <5 ppm to avoid sensitisation risk. Therapeutic effects require sustained dosing of 6–12 weeks minimum before assessment.
Key Studies
| Study | Design | Population | Key Result |
|---|---|---|---|
| Birks & Evans 2009 (Cochrane) | Systematic review, 36 RCTs; 9 high-quality trials (n>200, EGb 761, ≥24 weeks) | Patients with cognitive impairment or dementia of various causes | Small cognitive improvements (SMD ~−0.2 to −0.5) vs. placebo in some individual trials; inconsistent across review. Conclusion: “No convincing evidence that Ginkgo biloba is efficacious for dementia or cognitive impairment.” High heterogeneity throughout. |
| GuidAge (GIEM) trial 2012 | RCT, 5 years | n=3,069 elderly with memory complaints; EGb 761 240 mg/day vs. placebo | No reduction in Alzheimer’s disease conversion rate (HR 0.84, 95% CI 0.60–1.18, p=0.306). Largest single dementia prevention trial of ginkgo; negative result. |
| Weinmann et al. 2010 and claudication meta-analyses | Systematic review / meta-analysis of claudication RCTs | Patients with intermittent claudication; EGb 761 120–160 mg/day | Pain-free walking distance improved by 30–100 m vs. placebo across RCTs. Comparable to pentoxifylline in some head-to-head trials. Evidence Grade: Moderate — consistent direction, modest but reproducible effect. |
Evidence summary: The claudication data represent ginkgo’s most consistent clinical signal — multiple RCTs show reproducible improvements in walking distance that align mechanistically with PAF antagonism and NO-mediated vasodilation. Dementia evidence is weak and the GuidAge trial (the largest and longest) was negative for Alzheimer’s prevention. Tinnitus data are inconsistent and insufficient to recommend as a primary indication. The global popularity of ginkgo for cognitive enhancement far outpaces the strength of its evidence base in this indication.
Safety & Interactions
- Common adverse effects at standard doses: headache, GI upset, dizziness, allergic skin reactions. Generally well-tolerated. Spontaneous subdural haematoma reported rarely.
- Warfarin / anticoagulants (clinically significant): Ginkgolide B PAF antagonism + antiplatelet activity = additive bleeding risk with warfarin. Case reports of clinically significant bleeding, including subdural haematoma. INR monitoring is essential if co-prescribed; consider risk-benefit carefully.
- Aspirin / NSAIDs / clopidogrel: Additive antiplatelet effects; increased spontaneous bleeding risk. The combination of ginkgo + aspirin is particularly common and potentially hazardous in elderly patients.
- Anticonvulsants (phenytoin, carbamazepine): Ginkgo may lower seizure threshold (mechanism unclear, separate from seed ginkgotoxin). Clinical relevance uncertain; caution in patients with seizure history or on anticonvulsants.
- CYP2C9 substrates: Ginkgo modestly inhibits CYP2C9 in vitro; clinical significance for warfarin (a CYP2C9 substrate) is unclear but adds to the overall interaction concern warranting INR monitoring.
- Trazodone: A case report of coma in an Alzheimer’s patient co-prescribed ginkgo and trazodone. Mechanism unknown; caution advised.
- Contraindications: Known hypersensitivity; high bleeding-risk patients on anticoagulants; raw ginkgo seed ingestion (ginkgotoxin seizure risk). Discontinue 2–3 weeks before elective surgery. Avoid in pregnancy (theoretical uterotonic effect of ginkgolides).
Connections
References
- Birks J, Evans JG. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;(1):CD003120. doi:10.1002/14651858.CD003120.pub3
- Weinmann S, Roll S, Schwarzbach C, et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010;10:14. doi:10.1186/1471-2318-10-14
- Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11(10):851-9. doi:10.1016/S1474-4422(12)70206-5
- Evans WC. Trease and Evans’ Pharmacognosy. 16th ed. Saunders; 2009. Publisher link